Joshua Resnick - Jun 18, 2025 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Director
Signature
/s/ Shane Ward, Attorney-in-Fact
Stock symbol
CDTX
Transactions as of
Jun 18, 2025
Transactions value $
$0
Form type
4
Date filed
6/18/2025, 05:09 PM
Previous filing
Jun 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Resnick Joshua Director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO /s/ Shane Ward, Attorney-in-Fact 2025-06-18 0001690959

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Stock Option (right to buy) Award $0 +5.08K $0.00 5.08K Jun 18, 2025 Common Stock 5.08K $21.31 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Annual director stock option grant of 11,100 shares is pro-rated based on the number of days served on the Issuer's board of directors prior to the grant date divided by 365 days.
F2 The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders.
F3 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.